Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/516647
Metabolic Endocrinology - Type I Diabetes Drug Pipeline Report
Description:
Life Science Analytics, "Metabolic Endocrinology - Type I Diabetes Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of type i diabetes drugs by company and by stage as well as a summary of the latest news and developments in this area.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Scope of the report:
Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.
In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.
Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.
Key benefits
- Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.
- Keep track of your competitors and partners by better understanding their product pipeline.
- Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.
- Maintain a critical competitive advantage.
Contents:
RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Type I Diabetes Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects
--Top Companies in late stage Type I Diabetes Projects
--AutoImmune Inc
--AmCyte Inc.
--BTG plc
--Bayhill Therapeutics, Inc.
--DeveloGen AG
--Chong Kun Dang Pharmaceutical Corp.
--Pharm)
--Diamyd Medical AB
--Diabetology Ltd
--Generex Biotechnology Corporation
--Eli Lilly & Co
--Insmed Incorporated
--GlaxoSmithKline plc
--MacroGenics Inc.
--Living Cell Technologies Ltd
--Osiris Therapeutics Inc
--Novocell, Inc.
--Tolerx, Inc.
--Procter & Gamble Company
--Top Companies in early stage Type I Diabetes Projects
--Alba Therapeutics Corporation
--AdPharma, Inc.
--FIT Biotech Oyj Plc.
--DiaKine Therapeutics, Inc.
--Geron Corporation
--Genzyme Corporation
--Living Cell Technologies Ltd
--Lipoxen
--MultiCell Technologies Inc
--MicroIslet, Inc.
--Oramed Pharmaceuticals Inc
--Novocell, Inc.
--ReNeuron Group plc
--Plantigen Inc.
--Target-In Ltd.
--Schering-Plough Corp
Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Type I Diabetes Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects
--Top Companies in late stage Type I Diabetes Projects
--AutoImmune Inc
--AmCyte Inc.
--BTG plc
--Bayhill Therapeutics, Inc.
--DeveloGen AG
--Chong Kun Dang Pharmaceutical Corp.
--Pharm)
--Diamyd Medical AB
--Diabetology Ltd
--Generex Biotechnology Corporation
--Eli Lilly & Co
--Insmed Incorporated
--GlaxoSmithKline plc
--MacroGenics Inc.
--Living Cell Technologies Ltd
--Osiris Therapeutics Inc
--Novocell, Inc.
--Tolerx, Inc.
--Procter & Gamble Company
--Top Companies in early stage Type I Diabetes Projects
--Alba Therapeutics Corporation
--AdPharma, Inc.
--FIT Biotech Oyj Plc.
--DiaKine Therapeutics, Inc.
--Geron Corporation
--Genzyme Corporation
--Living Cell Technologies Ltd
--Lipoxen
--MultiCell Technologies Inc
--MicroIslet, Inc.
--Oramed Pharmaceuticals Inc
--Novocell, Inc.
--ReNeuron Group plc
--Plantigen Inc.
--Target-In Ltd.
--Schering-Plough Corp
Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Saturday, May 18, 2013
9:32:32 PM
9:32:32 PM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Metabolic Endocrinology - Type I Diabetes Drug Pipeline Report
Web Address
http://www.researchandmarkets.com/reports/516647
Office Code
OC8DIQSSTOWQQW
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Hard Copy |
|
EURO€ 834.00 + EUR€ 50.00 Shipping/Handling * |
|---|---|---|
| Electronic (PDF) |
|
EURO€ 765.00 |
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Saturday, May 18, 2013
9:32:32 PM
9:32:32 PM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp